EDWARD T. YEH, M.D.
Osteopathic Medicine at Holcombe Blvd, Houston, TX
License number
Texas J5068
Category
Osteopathic Medicine
Type
Cardiovascular Disease
Address
Address
1515 Holcombe Blvd, Houston, TX 77030
Phone
(713) 792-6161
(713) 792-2991
(713) 792-2991
Personal information
See more information about EDWARD T. YEH at radaris.comName
Address
Phone
5609 John Stockbauer Dr APT 39, Victoria, TX 77904
4012 Villanova St, Houston, TX 77005
17106 Rolling Brook Ct, Sugar Land, TX 77479
5609 John Stockbauer Dr, Victoria, TX 77904
106 Ashland Crk, Victoria, TX 77901
Professional information
Senp1 As A Marker Of Cancer Development And Target For Cancer Therapy
US Patent:
2006005, Mar 16, 2006
Filed:
Aug 29, 2005
Appl. No.:
11/214440
Inventors:
Edward Yeh - Houston TX, US
International Classification:
C12Q 1/68, G01N 33/574
US Classification:
435006000, 435007230
Abstract:
The present invention relates to compositions and methods for the use of SENP1 as a marker for cancer diagnosis, specifically prostate cancer. Still further, it relates to the use of inhibitors of SENP1 to inhibit cell proliferation of a neoplasm or tumor cell and to treat a hyperproliferative disease.
Edward T Yeh, Houston TX
Specialties:
Internal Medicine, Cardiovascular Disease, Cardiology
Work:
Univ. of Texas M.D. Anderson C.
1515 Holcombe Blvd, Houston, TX 77030
1515 Holcombe Blvd, Houston, TX 77030
Education:
University of California at Davis (1980)
Methods And Compositions Relating To Fortilin, An Anti-Apoptotic Molecule, And Modulators Of Fortilin
US Patent:
2003017, Sep 11, 2003
Filed:
Oct 30, 2001
Appl. No.:
10/021753
Inventors:
Ken Fujise - Houston TX, US
Edward Yeh - Houston TX, US
Edward Yeh - Houston TX, US
International Classification:
A01K067/00, A61K039/395
US Classification:
800/010000, 424/155100
Abstract:
The polypeptide Fortilin (also known as Translationally Controlled Tumour Protein, TCTP) specifically interacts with p53, a tumor suppressor involved in the induction of apoptosis and the normal growth regulation of a cell. Fortilin also specifically binds MCL1 (Myeloid Cell Leukemia 1). Fortilin has the ability to prevent apoptosis, which may be unregulated in hyperproliferative cells. The present invention is directed at compositions and methods involving a Fortilin modulator, which can induce apoptosis, for the prevention, treatment, or diagnosis of hyperproliferative diseases and conditions, including cancer and atherosclerosis. It is directed also at compositions and methods involving Fortilin, which can inhibit apoptosis, for the treatment of diseases and condition characterized by apoptosis, including certain vascular conditions.
Composition And Methods Relating To Senp1-A Sentrin-Specific Protease
US Patent:
2006013, Jun 22, 2006
Filed:
Jul 22, 2003
Appl. No.:
10/624945
Inventors:
Edward Yeh - Houston TX, US
Limin Gong - Pearland TX, US
Limin Gong - Pearland TX, US
International Classification:
C07H 21/04, C12P 21/06, C12N 9/64
US Classification:
435069100, 435226000, 435320100, 435325000, 536023200
Abstract:
The invention relates to a novel protease, called SENP1, which is active against sentrin-modified proteins in vivo. The invention more specifically relates to the genomic and amino acid sequences for SENP1, compositions related to and based on these sequences, and methods of using these sequences and compositions.
Inhibition Of Atherosclerosis By Diindolylmethane Analogs
US Patent:
2006007, Apr 13, 2006
Filed:
May 20, 2005
Appl. No.:
11/133679
Inventors:
Stephen Safe - Bryan TX, US
Ismael Samudio - Houston TX, US
Paolo Calabro - Naples, IT
Edward Yeh - Houston TX, US
Ismael Samudio - Houston TX, US
Paolo Calabro - Naples, IT
Edward Yeh - Houston TX, US
Assignee:
The Texas A&M University System - College Station TX
International Classification:
A61K 31/405
US Classification:
514414000
Abstract:
Diindolylmethane analogs such as 1,1-bis(3′-indolyl)-1-(p-substituted phenyl)methanes can be used to treat atherosclerosis and other vascular disease states. The analogs have been shown to display antiinflammatory effects in endothelial cells, suggesting their clinical applicability.
Use Of Peripheral Blood Cells For Cardiac Regeneration
US Patent:
2005023, Oct 20, 2005
Filed:
Mar 28, 2005
Appl. No.:
11/091149
Inventors:
Edward Yeh - Houston TX, US
International Classification:
A61K048/00, C12N005/08
US Classification:
424093210, 435372000
Abstract:
The present invention concerns methods of improving cardiac function in cardiac tissues of a recipient host by delivery of peripheral blood derived stem cells. The present invention also describes methods of stimulating cardiac tissue regeneration in a recipient host. Methods of treating a diseased cardiac tissue in a recipient host, as well as methods of obtaining a differentiated cardiac cell. Cardiac tissues subjected to these methods may be diseased or damaged, for example, by infarction, ischemia, chemotherapy, or infection. Peripheral blood derived stem cells used in the invention form new cardiomyocytes and also may form smooth muscle and endothelial cells.
Inhibitors Of C-Reactive Protein Induced Inflammation
US Patent:
2002014, Oct 3, 2002
Filed:
Jun 8, 2001
Appl. No.:
09/878124
Inventors:
Edward Yeh - Houston TX, US
Vincenzo Pasceri - Rome, IT
James Willerson - Houston TX, US
Vincenzo Pasceri - Rome, IT
James Willerson - Houston TX, US
Assignee:
Board of Regents, The University of Texas System
International Classification:
C12Q001/00, G01N033/53, G01N033/537, G01N033/543
US Classification:
435/004000, 435/007920
Abstract:
The present invention relates to methods and compositions for use in treating cardiovascular disease and other inflammatory disorders that are augmented by C-reactive protein. More particularly, the invention relates to methods for screening for modulators that inhibit C-reactive protein and the use of these modulators to inhibit C-reactive protein induced vascular inflammation.